Sinogel 1x 3,0 ml (MHD 31.07.2026) MiM Pharma GmbH Pain and limitation of joint

Pain and limitation of joint mobility in degenerative changes of the knee joint and other synovial joints

Manufacturer InformationName: Croma Pharma GmbHAddress: Industriezeile 6

and dark circles

• Bei Auftreten von venösen oder lymphatischen Stauungen in der betroffenen Extremität sollte Hylan G-F 20 nicht ins Gelenk injiziert werden

Sinogel 1x 3,0 ml (MHD 31.07.2026) MiM Pharma GmbH Pain and limitation of jointSINOGEL 3 ml Instructions for use Description Osteoarthritis (OA) is a chronic degenerative disease characterized by progressive damage to the articular cartilage, narrowing of the joint space, remodeling of the subchondral bone, formation of marginal joint osteophytes, and synovitis. Optimal OA therapy consists of an intra articular injection of exogenous hyaluronic acid, which can relieve symptoms by restoring the viscoelastic properties of synovial